

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM542358

SUBMISSION TYPE:		NEW ASSIGNMENT	
NATURE OF CONVEYANCE:		RELEASE OF SECURITY INTEREST	
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
NOVELION THERAPEUTICS INC. (f/k/a QLT, INC.)	FORMERLY QLT, INC.	09/24/2019	Corporation: BRITISH COLUMBIA
RECEIVING PARTY DATA			
Name:	AEGERION PHARMACEUTICALS, INC.		
Street Address:	One Main Street, Suite 800		
City:	Cambridge		
State/Country:	MASSACHUSETTS		
Postal Code:	02142		
Entity Type:	Corporation: MASSACHUSETTS		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Registration Number:	4589120	MYALEPT	
Registration Number:	4607022	MYALEPT	
Serial Number:	85484680	LEPTREEV	
Serial Number:	85484672	MYMLEP	
Serial Number:	85484679	PAZLEP	
Serial Number:	86786387	BYMYSIDE	
Serial Number:	86786368	BYMYSIDE	
CORRESPONDENCE DATA			
Fax Number:	6465584180		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2124597115		
Email:	TRoot@goodwinlaw.com		
Correspondent Name:	Troy Root		
Address Line 1:	620 8th Avenue		
Address Line 4:	New York, NEW YORK 10018		
ATTORNEY DOCKET NUMBER:	136665-277798		
NAME OF SUBMITTER:	Troy Root		
SIGNATURE:	/s/ Troy Root		

Delaware

OP \$190.00 4589120

DATE SIGNED:	09/24/2019
Total Attachments: 4 source=Aegerion Restructuring -- Novelion Release of Trademarks (QLT) [Execution]#page1.tif source=Aegerion Restructuring -- Novelion Release of Trademarks (QLT) [Execution]#page2.tif source=Aegerion Restructuring -- Novelion Release of Trademarks (QLT) [Execution]#page3.tif source=Aegerion Restructuring -- Novelion Release of Trademarks (QLT) [Execution]#page4.tif	

TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS (the "Release") is made this 24th day of September, 2019 (the "Release Date") by **NOVELION THERAPEUTICS INC. (f/k/a QLT, INC.)**, a corporation incorporated under the laws of British Columbia (the "Novelion") for the benefit of **AEGERION PHARMACEUTICALS, INC.**, a Delaware corporation (the "Grantor"), with its principal place of business located at One Main Street, Suite 800, Cambridge, Massachusetts 02142.

WHEREAS, the Grantor has entered into that certain Trademark Security Agreement, dated as of June 14, 2016 with Novelion (as at any time prior to the date hereof amended, supplemented or otherwise modified, the "Security Agreement"), pursuant to which Grantor granted to Novelion a continuing security interest in all right, title or interest in, to or under all of the following assets, licenses or other rights whether now or at any time hereafter owned or acquired by, or arising in favor of, such Grantor (collectively, the "Trademark Collateral"):

- A. all Trademarks listed on Schedule I thereto;
- B. all goodwill associated with or symbolized by the Trademarks identified in clause (A) above;
- C. all assets, rights and interests that uniquely reflect or embody the Trademarks identified in clause (A) above;
- D. any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligations, to sue and collect damages for said use or infringement of any Trademark identified in clause (A) above;
- E. all amendments, renewals and extensions of any of the foregoing; and
- F. all proceeds of and rights associated with the foregoing (the "Marks");

WHEREAS, Novelion has recorded with the United States Patent and Trademark Office (the "USPTO"), at Reel 5814, Frame 0499, notices of security interests in the Marks; and

WHEREAS, all outstanding amounts owed under any financing documents executed in connection with the Security Agreement have been satisfied and the Grantor has requested that Novelion release its security interest in the Marks.

NOW THEREFORE, in consideration thereof and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Novelion agrees as follows:

1. Release of Security Interest. Effective as of the Release Date, Novelion hereby irrevocably and forever terminates, releases and discharges any and all security interests in the Marks granted by the Grantor under the Security Agreement.

2. Recordation of Release. Novelion understands and agrees that this Release may be recorded by or for the Grantor with the USPTO.


3. Further Actions. Novelion further agrees to execute any other documents and take any further action reasonably necessary in any state, country or jurisdiction that the Grantor may reasonably require to effect the intent and purpose of this Release, provided that all such documents are to be prepared by counsel to the Grantor and the cost and expense of such documents and actions shall be borne solely by the Grantor.

4. Capitalized Terms. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Security Agreement, as applicable.

[Signature page follows]

IN WITNESS WHEREOF, Novelion has caused this Release to be executed as an instrument under seal by its duly authorized officer as of the Release Date.

NOVELION THERAPEUTICS INC.
(f/k/a QTL, INC.)

By: 
Name: Ben Harshbarger
Title: Interim Chief Executive Officer and
General Counsel

[Signature Page to Termination and Release of Security Interest in Trademarks]

TRADEMARK
REEL: 006762 FRAME: 0694

SCHEDULE I

TRADEMARKS

Trademark	Status	Country	Application No./ Registration No.
MYALEPT	Registered	United States	85/484,675
			4,589,120
MYALEPT LOGO	Registered	United States	86/043,958
			4,607,022
LEPTREEV	Abandoned	United States	85/484,680
MYMLEP	Abandoned	United States	85/484,672
PAZLEP	Abandoned	United States	85/484,679
BYMYSIDE	Pending	United States	86/786,387
BYMYSIDE LOGO	Pending	United States	86/786,368

TRADEMARK

REEL: 006762 FRAME: 0695

RECORDED: 09/24/2019